Sub-Group Analysis of Novocure's EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma ...
Medical Health News,
ST. HELIER, Jersey--( BUSINESS WIRE )--Novocure (NASDAQ:NVCR) announced today that the results of a retrospective post-hoc sub-gr…